The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
The firm said that the new financing will help it accelerate commercial initiatives in the US, Europe, Brazil, and Canada.
Proscia said that its partnership with Johns Hopkins, which aims to accelerate research breakthroughs and improve patient outcomes, is one among a number of its recent pathology-related engagements.
Philips and Paige said that through their collaboration they aim to provide digital pathology technologies for routine clinical practice.
The companies will develop an integrated clinical pathology solution with plans to submit a 510(k) application to the US Food and Drug Administration.
Called Ion, the system combines low magnification, high-resolution imaging with a proprietary image analysis algorithm for rapid pathogen detection.
The IMCB-A!maginostic Joint Lab of Excellence will provide AI- and machine learning-based solutions to support computational digital and multiplex pathology.
The Finnish company also announced that it has received CE-IVD marking for its Aiforia Clinical pathology image analysis platform.
The firms are collaborating to provide reference architectures for whole-slide image viewing and managing to healthcare and life sciences organizations.
The firm said that receipt of the CE mark accelerates its entry into the diagnostic pathology market in Europe and other key geographies globally.